Get the Stockscreener App
43.50
0.51%
0.22
Pre-market:
44.73
1.23
+2.83%
Crinetics Pharmaceuticals Inc stock is traded at $43.50, with a volume of 1.05M.
It is up +0.51% in the last 24 hours and up +4.44% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$43.28
Open:
$43.12
24h Volume:
1.05M
Relative Volume:
0.72
Market Cap:
$4.10B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-11.66
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
+6.12%
1M Performance:
+4.44%
6M Performance:
+30.28%
1Y Performance:
-22.27%
1-Day Range:
$42.76
$44.20
1-Week Range:
$41.10
$44.70
52-Week Range:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
43.50 | 4.08B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Identifying reversal signals in Crinetics Pharmaceuticals Inc.2025 Performance Recap & Growth-Oriented Investment Plans - newser.com
Top chart patterns to watch in Crinetics Pharmaceuticals Inc.Weekly Trade Summary & Verified Momentum Watchlists - newser.com
How interest rate cuts could boost Crinetics Pharmaceuticals Inc. stockWeekly Trade Summary & Low Drawdown Investment Strategies - newser.com
Chart based analysis of Crinetics Pharmaceuticals Inc. trendsJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Can Crinetics Pharmaceuticals Inc. (6Z4) stock deliver double digit returnsMarket Volume Report & Low Drawdown Momentum Trade Ideas - newser.com
Is Crinetics Pharmaceuticals Inc. stock entering bullish territoryInflation Watch & Real-Time Chart Pattern Alerts - newser.com
Pier Capital LLC Boosts Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals Inc. stock trend outlook and recovery path2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
Crinetics Pharmaceuticals, Inc. $CRNX Shares Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.2025 Earnings Surprises & Stepwise Trade Signal Guides - newser.com
Will Crinetics Pharmaceuticals Inc. (6Z4) stock rise with strong economyJuly 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Why Crinetics Pharmaceuticals Inc. (6Z4) stock attracts HNW investorsNew Guidance & Real-Time Market Trend Scan - newser.com
Can Crinetics Pharmaceuticals Inc. rally from current levelsJuly 2025 Sector Moves & Free Community Supported Trade Ideas - newser.com
Analyzing recovery setups for Crinetics Pharmaceuticals Inc. investorsM&A Rumor & Short-Term High Return Strategies - newser.com
Is Crinetics Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
Automated trading signals detected on Crinetics Pharmaceuticals Inc.July 2025 Trends & Stepwise Trade Signal Guides - newser.com
Crinetics (CRNX) Is Up 6.1% After New Paltusotine Data Presented at Neuroendocrine Tumor Meeting - Sahm
Crinetics Pharmaceuticals Inc 6Z4 Stock Analysis and ForecastSector Performance Review & Free Record-Breaking Gains - earlytimes.in
Using data tools to time your Crinetics Pharmaceuticals Inc. exit2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
Why Crinetics Pharmaceuticals Inc. is moving todayQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Jennison Associates LLC Has $57.15 Million Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Will Crinetics Pharmaceuticals Inc. benefit from macro trendsWeekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
Crinetics Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
Will Crinetics Pharmaceuticals Inc. stock keep outperforming rivals2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
What dividend safety rating applies to Crinetics Pharmaceuticals Inc. (6Z4) stock2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
Backtesting results for Crinetics Pharmaceuticals Inc. trading strategies2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Published on: 2025-10-30 23:11:05 - newser.com
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent 50% Three-Month Share Price Rally - Sahm
Crinetics Pharmaceuticals: Its Post-FDA Approval Future (NASDAQ:CRNX) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) to Release Quarterly Earnings on Thursday - MarketBeat
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Oct 01 '25 |
Sale |
41.81 |
5,000 |
209,050 |
66,270 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):